Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Silani Vincenzo) "

Sökning: WFRF:(Silani Vincenzo)

  • Resultat 21-28 av 28
  • Föregående 12[3]
Sortera/gruppera träfflistan
  • Van Der Spek, Rick A., et al. (författare)
  • Reconsidering the causality of TIA1 mutations in ALS
  • 2018
  • Ingår i: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. - : TAYLOR & FRANCIS LTD. - 2167-8421 .- 2167-9223. ; 19:1-2, s. 1-3
  • Tidskriftsartikel (övrigt vetenskapligt)
  • van Doormaal, Perry T. C., et al. (författare)
  • The role of de novo mutations in the development of amyotrophic lateral sclerosis
  • 2017
  • Ingår i: Human Mutation. - : John Wiley & Sons. - 1059-7794 .- 1098-1004. ; 38:11, s. 1534-1541
  • Tidskriftsartikel (refereegranskat)abstract
    • The genetic basis combined with the sporadic occurrence of amyotrophic lateral sclerosis (ALS) suggests a role of de novo mutations in disease pathogenesis. Previous studies provided some evidence for this hypothesis; however, results were conflicting: no genes with recurrent occurring de novo mutations were identified and different pathways were postulated. In this study, we analyzed whole-exome data from 82 new patient-parents trios and combined it with the datasets of all previously published ALS trios (173 trios in total). The per patient de novo rate was not higher than expected based on the general population (P = 0.40). We showed that these mutations are not part of the previously postulated pathways, and gene-gene interaction analysis found no enrichment of interacting genes in this group (P = 0.57). Also, we were able to show that the de novo mutations in ALS patients are located in genes already prone for de novo mutations (P < 1 x 10(-15)). Although the individual effect of rare de novo mutations in specific genes could not be assessed, our results indicate that, in contrast to previous hypothesis, de novo mutations in general do not impose a major burden on ALS risk.
  • van Rheenen, Wouter, et al. (författare)
  • Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis
  • 2016
  • Ingår i: Nature Genetics. - 1061-4036 .- 1546-1718. ; 48:9, s. 1043-1048
  • Tidskriftsartikel (refereegranskat)abstract
    • To elucidate the genetic architecture of amyotrophic lateral sclerosis (ALS) and find associated loci, we assembled a custom imputation reference panel from whole-genome-sequenced patients with ALS and matched controls (n = 1,861). Through imputation and mixed-model association analysis in 12,577 cases and 23,475 controls, combined with 2,579 cases and 2,767 controls in an independent replication cohort, we fine-mapped a new risk locus on chromosome 21 and identified C21orf2 as a gene associated with ALS risk. In addition, we identified MOBP and SCFD1 as new associated risk loci. We established evidence of ALS being a complex genetic trait with a polygenic architecture. Furthermore, we estimated the SNP-based heritability at 8.5%, with a distinct and important role for low-frequency variants (frequency 1-10%). This study motivates the interrogation of larger samples with full genome coverage to identify rare causal variants that underpin ALS risk.
  • Zanchetti, Alberto, et al. (författare)
  • Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence.
  • 2014
  • Ingår i: Journal of Hypertension. - : Lippincott Williams & Wilkins. - 1473-5598. ; 32:9, s. 1741-1750
  • Forskningsöversikt (refereegranskat)abstract
    • It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these treatments can prevent cognitive decline after stroke.
Skapa referenser, mejla, bekava och länka
  • Resultat 21-28 av 28
  • Föregående 12[3]
Typ av publikation
tidskriftsartikel (27)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (24)
övrigt vetenskapligt (4)
Silani, Vincenzo (28)
van den Berg, Leonar ... (18)
Andersen, Peter M. (17)
Al-Chalabi, Ammar (15)
Veldink, Jan H. (15)
Landers, John E. (14)
visa fler...
Morrison, Karen E. (14)
Van Damme, Philip (13)
Hardiman, Orla (13)
Robberecht, Wim (13)
Shaw, Pamela J. (13)
Shaw, Christopher E. (12)
Chio, Adriano (12)
Shatunov, Aleksey (11)
Weber, Markus (11)
van Rheenen, Wouter (10)
Ludolph, Albert C (10)
van Es, Michael A (10)
Fogh, Isabella (10)
Glass, Jonathan D (9)
Ratti, Antonia (8)
de Carvalho, Mamede (8)
Gellera, Cinzia (8)
Traynor, Bryan J. (7)
Diekstra, Frank P (7)
D'Alfonso, Sandra (6)
Corcia, Philippe (6)
Weishaupt, Jochen H. (6)
Brown, Robert H (6)
Calvo, Andrea (6)
Van Deerlin, Viviann ... (6)
Tiloca, Cinzia (6)
Taroni, Franco (5)
Corrado, Lucia (5)
Meininger, Vincent (5)
Cereda, Cristina (5)
Comi, Giacomo P (5)
Leigh, P. Nigel (5)
Van Eijk, Kristel R. (4)
van Blitterswijk, Ma ... (4)
Talbot, Kevin (4)
Keagle, Pamela (4)
Calini, Daniela (4)
Petri, Susanne (4)
Powell, John (4)
McLaughlin, Russell ... (4)
Melki, Judith (4)
Turner, Martin R (4)
Lewis, Cathryn M. (4)
Brown, Robert H., Jr ... (4)
visa färre...
Umeå universitet (22)
Lunds universitet (4)
Linköpings universitet (2)
Karolinska Institutet (2)
Göteborgs universitet (1)
Uppsala universitet (1)
Engelska (28)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (24)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy